Table 1.
DDSs for single component from Danshen.
| Drug delivery systems | Materials | Drugs | Advantages | References | |
|---|---|---|---|---|---|
| Nanoparticles | Mesoporous silica nanoparticles | Rhodamine B; SBA-15-structured mesoporous silica | Sal B | Sustained-release property; high Sal B release rates; no visible cytotoxicity; good blood compatibility | (He et al., 2010) |
| Polymeric nanoparticles | PLGA, cardiolipin, DSPE-PEG (2000)-CA, FITC, PAAM | RA, CUR | High loading efficiency; no significant toxicity; higher BBB permeability coefficient | (Kuo & Tsai, 2018) | |
| Poly (ethyl cyanoacrylate) nanoparticles | Monomer ECA, HCl, dextran 70000, anhydrous glucose, Tween 80 | Sal B | High encapsulation efficiency; sustained release | (Grossi et al., 2017) | |
| PLGAnanoparticles | PLGA, biotin-PEG-NH2, DCM, DCC, NHS, PVA | DHT I | Small particle size; narrow size distributions; sustained release property | (Luo et al., 2018) | |
| PEGylated nanoparticles | D, L-lactide, methoxy PEG-PLA/maleimide PEG-PLA, Sn (Oct)2 | Tan IIA | Better brain delivery efficacy; small particle size; high encapsulation efficiency | (Liu et al., 2013) | |
| Gold nanoparticles | KAuCl4, PEI, β-CD | Tan IIA, α-mangostin | Low cytotoxicity; enhanced efficacy | (Qiu et al., 2016) | |
| Solid lipid nanoparticles | Soy lecithin, lipid matrix, Tween 80, sodium dehydrocholate | CPT | Improved bioavailability; stable | (Hu et al., 2010) | |
| Targeted nanoparticles | mPEG-PLGA-PLL-cRGD, F68, | Tan IIA | Even size distribution; stable; extended drug releasing time; improved tumor-targeting activity | (Wang et al., 2014) | |
| Liposomes | Liposomes | P90G, cholesterol, PEG 2000 | Sal B | Narrow size distribution; eliminate irreversible adsorptive loss; ameliorat drug delaying | (Isacchi et al., 2011) |
| Emulsion | Microemulsion | Phospholipid, glycerol, pluronic F68 | Tan IIA | Safe used for iv injection; enhance antitumor effect | (Ma et al., 2013) |
| Lipid emulsion | Soybean oil, MCT, soybean lecithin, Poloxamer 188, glycerol | Tan IIA | Enhanced efficacy; reduced systematical toxicity; physico-chemically stable | (Chu et al., 2012) | |
| Nanoemulsion | Ethyl oleate, oleic acid, IPM, GTCC, Capryol 90, lactoferrin-mPEG5000 | Tan I | Stable with a smaller droplet size in nano-range; efficient delivery of drugs to brain | (Wu et al., 2019) | |
| Pellets | Pellets | Sodium caprate, MCC, PVP, Eudragit RS30D/RL30D | DSS | Prolonged release; improved oral bioavailability | (Yu et al., 2017) |
| Pellets | PVP, poloxamer 188, Opadry II, PVAc, PVA-PEG | Tan IIA | Stable and improved efficacy; chronotherapeutic modified-release. | (Yan et al., 2015) | |
| Phospholipids complex loaded pellets | Lipoid S100, chloroform | Sal B | Improved lipo-solubility and permeability; great oral bioavailability | (Li et al., 2013) | |
| Proliposomes loaded pellets | Lipoid S100, cholesterol, mannitol, carrageenan | PD | Enhanced encapsulation efficiency; sustained release | (Zhang et al., 2016a) | |
| Micelles | Micelles | TPGS-g-PLGA, Pluronic F68 | Tan IIA | Improved bioavailability; mono-dispersed; small particle size; high encapsulation efficiency; highly stable; sustained release; enhanced anti-cancer effects | (Zhang et al., 2014) |